"Usefulness of continuous interstitial glucose in diabetic patient undergoing hemodialysis
Authors' conclusion
HbA1c alone may substantially underestimate glycemic burden in patients on hemodialysis. CGM provides a more accurate assessment of glucose control and reveals undetected hypo- and hyperglucose levels. Incorporating CGM into routine care may improve diabetes management and therapeutic decision-making in this high-risk population.
Study context
- Population
- Patients >18 years with T2D undergoing hemodialysis
- Participants
- 41 patients
- Exposure
- 14-day continuous glucose monitoring (CGM) vs HbA1c for assessing glycaemic control
- Outcome
- Glycaemic control assessed by CGM (FreeStyle) compared with HbA1c
- Follow-up
- 14 days
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
Glycaemic targets met: HbA1c <8% vs CGM targets
- HbA1c < 8 %
- 68 %
- Met CGM targets
- 21 %
- P for difference
- P < 0.005
Observational data: associations, not effects.
Further findings
Mean glucose on dialysis days
- Mean glucose significantly lower on dialysis days, without increase in hypoglycaemic episodes
- −13 mg/dl, P < 0.0001
Discrepancy between HbA1c and CGM metrics
- Discrepancies associated with diabetes-related nephropathy and longer hemodialysis (HD) duration
Original publication
"Usefulness of continuous interstitial glucose in diabetic patient undergoing hemodialysis. Diabetes Metab. Published 4 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →